Literature DB >> 28496718

Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options.

David L Johnson1, John D Day1, Srijoy Mahapatra2, T Jared Bunch1.   

Abstract

Atrial Fibrillation (AF) continues to increase in prevalence and its' consequences and disease associations have a great impact on multiple aspects of medical practice. As such, making preventive strategies to minimize risk of the arrhythmia and its' complications are paramount to improve quality of life, mortality, and limit medical resource utilization. To the extent that AF independently impacts adverse cardiovascular outcomes, this review article will focus on these outcomes, in particular heart failure (HF), stroke, and mortality, and discuss contemporary strategies for treatment. Conclusions: AF has a marked deleterious impact on the lives of patients. This impact can be accelerated when other cardiac diseases coexist. Although rhythm control strategies have been an intriguing tool to reverse or minimize the adverse outcomes associate with AF, they have largely been unsuccessful. In general, failures of currently available AADs to improve survival are due to failure of the drug to maintain sinus rhythm and presence of drug toxicities. Early data with ablation approaches are favorable and support rhythm control strategies to minimize long-term risks associated with AF. However, most of the data stem from observational analysis or small randomized trials. Large randomized prospective trials will ultimately define the role of catheter ablation in the management of AF patients.

Entities:  

Year:  2012        PMID: 28496718      PMCID: PMC5153007          DOI: 10.4022/jafib.477

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  78 in total

1.  The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.

Authors:  Sakis Themistoclakis; Andrea Corrado; Francis E Marchlinski; Pierre Jais; Erica Zado; Antonio Rossillo; Luigi Di Biase; Robert A Schweikert; Walid I Saliba; Rodney Horton; Prasant Mohanty; Dimpi Patel; David J Burkhardt; Oussama M Wazni; Aldo Bonso; David J Callans; Michel Haissaguerre; Antonio Raviele; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

2.  Natural history and long-term outcomes of ablated atrial fibrillation.

Authors:  Ayman A Hussein; Walid I Saliba; David O Martin; Mandeep Bhargava; Minerva Sherman; Christina Magnelli-Reyes; Mohammed Chamsi-Pasha; Seby John; Michelle Williams-Adrews; Bryan Baranowski; Thomas Dresing; Thomas Callahan; Mohamed Kanj; Patrick Tchou; Bruce D Lindsay; Andrea Natale; Oussama Wazni
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-04-14

3.  Chronic heart failure and the substrate for atrial fibrillation.

Authors:  Arun Sridhar; Yoshinori Nishijima; Dmitry Terentyev; Mahmood Khan; Radmila Terentyeva; Robert L Hamlin; Tomohiro Nakayama; Sandor Gyorke; Arturo J Cardounel; Cynthia A Carnes
Journal:  Cardiovasc Res       Date:  2009-06-30       Impact factor: 10.787

Review 4.  Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets.

Authors:  Joachim R Ehrlich; Stanley Nattel; Stefan H Hohnloser
Journal:  J Cardiovasc Electrophysiol       Date:  2002-04

5.  Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation.

Authors:  Marcos Daccarett; Troy J Badger; Nazem Akoum; Nathan S Burgon; Christian Mahnkopf; Gaston Vergara; Eugene Kholmovski; Christopher J McGann; Dennis Parker; Johannes Brachmann; Rob S Macleod; Nassir F Marrouche
Journal:  J Am Coll Cardiol       Date:  2011-02-15       Impact factor: 24.094

Review 6.  Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.

Authors:  Paulus Kirchhof; Gregory Y H Lip; Isabelle C Van Gelder; Jeroen Bax; Elaine Hylek; Stefan Kaab; Ulrich Schotten; Karl Wegscheider; Giuseppe Boriani; Axel Brandes; Michael Ezekowitz; Hans Diener; Laurent Haegeli; Hein Heidbuchel; Deirdre Lane; Luis Mont; Stephan Willems; Paul Dorian; Maria Aunes-Jansson; Carina Blomstrom-Lundqvist; Maria Borentain; Stefanie Breitenstein; Martina Brueckmann; Nilo Cater; Andreas Clemens; Dobromir Dobrev; Sergio Dubner; Nils G Edvardsson; Leif Friberg; Andreas Goette; Michele Gulizia; Robert Hatala; Jenny Horwood; Lukas Szumowski; Lukas Kappenberger; Josef Kautzner; Angelika Leute; Trudie Lobban; Ralf Meyer; Jay Millerhagen; John Morgan; Felix Muenzel; Michael Nabauer; Christoph Baertels; Michael Oeff; Dieter Paar; Juergen Polifka; Ursula Ravens; Ludger Rosin; W Stegink; Gerhard Steinbeck; Panos Vardas; Alphons Vincent; Maureen Walter; Günter Breithardt; A John Camm
Journal:  Europace       Date:  2011-07-26       Impact factor: 5.214

7.  Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.

Authors:  Gregory Y H Lip
Journal:  Am J Med       Date:  2010-09-29       Impact factor: 4.965

8.  Increased atrial fibrillation mortality: United States, 1980-1998.

Authors:  Wendy A Wattigney; George A Mensah; Janet B Croft
Journal:  Am J Epidemiol       Date:  2002-05-01       Impact factor: 4.897

Review 9.  Status of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Med Clin North Am       Date:  2008-01       Impact factor: 5.456

10.  Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women.

Authors:  David Conen; Usha B Tedrow; Bruce A Koplan; Robert J Glynn; Julie E Buring; Christine M Albert
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.